关于桂林三金药业股份有限公司 2024 年第一次临时股东大会的法律意见书 致：桂林三金药业股份有限公司 受桂林三金药业股份有限公司（以下简称"公司"）聘请，北京市通商律师 事务所指派律师（以下简称"本所律师"）出席了公司 2024 年第一次临时股东 大会（以下简称"本次股东大会"），并依据《中华人民共和国公司法》（以下 简称"《公司法》"）、《上市公司股东大会规则》《深圳证券交易所上市公司 股东大会网络投票实施细则》等法律、法规、规章、规范性文件及《桂林三金药 业股份有限公司章程》（以下简称"《公司章程》"）的规定，对公司本次股东 大会召集及召开程序、出席会议的人员资格、召集人资格、提案审议情况、股东 大会的表决方式、表决程序和表决结果等重要事项的合法性进行了审核和见证， 现出具本法律意见书如下： 一、 本次股东大会的召集与召开程序 中国北京市建国门外大街 1 号国贸写字楼 2 座 12-15 层 100004 12-15th Floor, China World Office 2, No. 1 Jianguomenwai Avenue, Beijing 100004, China 电话 Tel: +86 1 ...

桂林三金药业股份有限公司投资者关系活动记录表 编号：2024033 | --- | --- | --- | |-------------------------|------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Investment Rating - The report assigns a rating of "Accumulate" (downgraded) for the company [4][5] Core Views - The company's core products are gradually recovering growth, while second-line products are showing stable expansion. The sales of key products like Sanjin Pian and Xigua Shuang have experienced fluctuations due to national policy adjustments, but the company has implemented targeted measures to stabilize sales [2][4] - The company's overall profitability remains stable, with a gross margin of 74.84%, an increase of 1.27 percentage points year-on-year. The operating cash flow has also improved by 1.45% year-on-year [3][4] Financial Performance Summary - For the first three quarters of 2024, the company achieved operating revenue of 1.575 billion yuan, a year-on-year decrease of 3.49%, and a net profit attributable to the parent company of 384 million yuan, down 3.28% year-on-year. However, in Q3 alone, the revenue was 506 million yuan, up 15.71% year-on-year, and the net profit attributable to the parent company was 82.9 million yuan, a significant increase of 377.72% year-on-year [1][4] - The company has adjusted its revenue forecasts for 2024-2025, lowering the expected operating revenue from 2.714 billion yuan and 3.148 billion yuan to 2.208 billion yuan and 2.407 billion yuan, respectively [4][5] Key Financial Metrics - The company reported a gross margin of 74.84% for the first three quarters of 2024, with a period expense ratio of 45.78%, which is an increase of 2.28 percentage points year-on-year. The sales expense ratio increased by 3.79 percentage points to 31.84% [3][4] - The company's total market capitalization is approximately 8.701 billion yuan, with a circulating market capitalization of about 8.279 billion yuan [5]

Investment Rating - The investment rating for the company is "Buy" (maintained) [3] Core Views - The company has shown a recovery trend in its main products, with significant growth in Q3 2024, achieving a revenue of 5.06 billion yuan (+15.71%) and a net profit of 0.83 billion yuan (+377.72%) [5][6] - The company is expected to maintain a high dividend payout ratio, with a proposed cash dividend of 1.47 billion yuan for the first three quarters of 2024, reflecting confidence in its stable profitability and financial health [7] - The company's net profit forecast for 2024-2026 is projected to be 4.6 billion yuan, 5.2 billion yuan, and 5.8 billion yuan respectively, with corresponding P/E ratios of 19, 17, and 15 [7] Financial Performance Summary - For the first three quarters of 2024, the company reported a revenue of 15.75 billion yuan (-3.49% YoY) and a net profit of 3.84 billion yuan (-3.28% YoY) [5] - The company’s industrial segment revenue for H1 2024 was 10.38 billion yuan (-5.6%), while the commercial circulation segment revenue was 0.22 billion yuan (-5.62%) [6] - The company’s total assets were reported at 3,934.30 million yuan, with a total market value of 8,737.15 million yuan [8] Earnings Forecast - The company is expected to achieve a revenue of 22.83 billion yuan in 2024, with a net profit of 4.59 billion yuan, reflecting a YoY growth of 9.1% [10] - The projected earnings per share (EPS) for 2024 is 0.78 yuan, with a gross margin of 74.9% [10] Market Performance - The company’s stock price is currently at 14.87 yuan, with a 52-week price range of 11.69-17.40 yuan [3][8] - The company has shown a relative performance against the CSI 300 index, with a 1-month absolute increase of 2.84% [4]

桂林三金药业股份有限公司投资者关系活动记录表 编号：2024032 | --- | --- | --- | |-------------------------|-------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | ...

Investment Rating - The investment rating for the company is "Buy" and is maintained [2][5]. Core Views - The company has shown significant improvement in Q3 performance, with revenue and profit growing rapidly. The Q3 revenue reached 5.06 billion yuan, an increase of 15.71%, and the net profit attributable to shareholders was 0.83 billion yuan, up 377.72% [3][4]. - The company is expected to stabilize and recover its performance in Q4 and the following year as the impact of high base factors diminishes [3][5]. Financial Performance Summary - For the first three quarters of 2024, the company reported a total revenue of 15.75 billion yuan, a decrease of 3.49%, and a net profit of 3.84 billion yuan, down 3.28%. However, the operating cash flow net amount was 2.34 billion yuan, an increase of 1.45% [3][4]. - The gross margin for the first three quarters of 2024 was 74.84%, an increase of 1.27 percentage points, while the net profit margin was 24.38%, up 0.05 percentage points [4]. - The company has a healthy cash flow, with cash and cash equivalents amounting to 9.67 billion yuan as of the end of September 2024, a year-on-year increase of 29% [4]. Earnings Forecast and Investment Suggestions - The company is expected to achieve revenues of 23.89 billion yuan, 26.39 billion yuan, and 29.16 billion yuan for the years 2024, 2025, and 2026, respectively. The net profit attributable to shareholders is projected to be 4.81 billion yuan, 5.31 billion yuan, and 5.87 billion yuan for the same years [5][6]. - The current stock price corresponds to a price-to-earnings ratio (PE) of 18.3, 16.6, and 15.0 for the years 2024, 2025, and 2026, respectively, supporting the "Buy" rating [5][6].

桂林三金药业股份有限公司（以下简称"公司"）于2024年10月29日召开第 八届董事会第十一次会议并通过决议，决定于2024年11月14日（星期四）召开公 司2024年第一次临时股东大会，现将本次股东大会的有关事项公告如下： 证券代码：002275 证券简称：桂林三金 公告编号：2024-030 桂林三金药业股份有限公司 关于召开2024年第一次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1．股东大会届次：2024年第一次临时股东大会 2．股东大会的召集人：公司董事会。公司第八届董事会第十一次会议审议 通过了《关于提请召开2024年第一次临时股东大会的议案》。 3．会议召开的合法、合规性：本次股东大会的召开符合有关法律法规、深 圳证券交易所业务规则和公司章程等的规定。 4．会议召开的日期、时间： 现场会议的召开时间：2024年11月14日（星期四）下午15:00； 网络投票时间：2024年11月14日。其中：通过深圳证券交易所交易系统投票 的时间为2024年11月14日9:15—9:25,9:30—11:30 和 ...

Financial Performance - The company's revenue for Q3 2024 reached ¥506,371,152.47, an increase of 15.71% compared to the same period last year[2] - Net profit attributable to shareholders was ¥82,903,467.75, representing a significant increase of 377.72% year-on-year[2] - The net profit after deducting non-recurring gains and losses was ¥72,755,225.11, up 657.38% from the previous year[2] - The company's basic earnings per share for the reporting period was ¥0.14, an increase of 374.58% year-on-year[2] - The net profit for Q3 2024 was CNY 383,875,851.70, a decrease of 3.5% compared to CNY 396,894,751.76 in Q3 2023[15] - The basic earnings per share for Q3 2024 was CNY 0.65, down from CNY 0.68 in Q3 2023[15] - The total comprehensive income for Q3 2024 was CNY 370,546,543.34, compared to CNY 371,553,461.38 in the same quarter last year[15] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,934,298,324.33, a slight decrease of 0.04% from the end of the previous year[2] - Total assets decreased slightly to CNY 3,934,298,324.33 from CNY 3,936,044,324.47[13] - Total liabilities decreased to CNY 920,161,549.26 from CNY 1,119,082,599.87, showing a reduction in financial obligations[12] - The company's equity attributable to shareholders increased to CNY 3,014,136,775.07 from CNY 2,816,961,724.60, indicating growth in shareholder value[13] Cash Flow - The cash flow from operating activities for the year-to-date was ¥233,794,725.21, showing a modest increase of 1.45%[2] - Cash flow from operating activities showed a net increase of CNY 233,794,725.21, compared to CNY 230,443,141.67 in the same period last year[16] - The company reported cash and cash equivalents at the end of Q3 2024 amounting to CNY 966,509,822.41, up from CNY 750,846,793.80 at the end of Q3 2023[17] - Cash inflow from investment activities was CNY 705,081,342.80, a decrease from CNY 722,623,764.67 in the previous year[16] - The cash outflow for financing activities was CNY 395,545,067.29, an increase from CNY 354,882,449.10 in the previous year[17] - The company experienced a foreign exchange impact of CNY -608,923.59 on cash and cash equivalents during the quarter[17] Shareholder Information - The total number of common shareholders at the end of the reporting period is 17,059[7] - Guilin Sanjin Group holds 62.07% of shares, amounting to 364,679,300 shares[7] - The largest individual shareholder, Weng Yuling, owns 4.99% of shares, totaling 29,300,061 shares[7] Investments and R&D - The company reported a significant increase in accounts receivable by 136.45% due to annual credit extensions to distributors[5] - The company’s long-term investments rose by 174.89% primarily due to additional investments in Chongqing Feifan[5] - Research and development expenses increased to CNY 114,851,241.90, up from CNY 105,333,389.85, reflecting a focus on innovation[14] Other Activities - The company provided a guarantee for its wholly-owned subsidiary with a maximum debt amount of RMB 20 million[9] - The actual controller and chairman, Zou Xun, completed a share buyback plan, acquiring 383,000 shares, which is 0.07% of the total share capital, for a total amount of RMB 5.0458 million[9] - The company announced the approval of a drug clinical trial for its subsidiary on August 27, 2024[8] - The company has not reported any changes in the participation of major shareholders in margin trading[8] - The company has not disclosed any preferred shareholders or their holdings[8] - The company’s board approved a guarantee for financing credit business for its subsidiary at two banks[9] - The company’s major shareholders have not participated in any securities lending activities[8] Operating Performance - Total operating revenue for the period was CNY 1,574,787,639.33, a decrease of 3.5% compared to CNY 1,631,768,174.65 in the previous period[14] - Total operating costs amounted to CNY 1,140,824,909.86, down 2.0% from CNY 1,164,661,454.27 in the prior period[14] - Accounts receivable rose significantly to CNY 187,038,420.53, compared to CNY 79,102,613.44 at the start of the period, indicating improved sales performance[11] - Inventory levels remained stable at CNY 256,292,292.87, compared to CNY 255,959,432.20 at the beginning of the period[11] - The company reported a net profit margin improvement, with net profit increasing due to cost control measures despite lower revenue[14]

证券代码：002275 证券简称：桂林三金 公告编号：2024-031 桂林三金药业股份有限公司 第八届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 桂林三金药业股份有限公司（以下简称"公司"）于2024年10月18日以书面 和电子邮件方式向董事和监事发出第八届董事会第十一次会议通知，会议于2024 年10月29日在广西壮族自治区桂林市临桂区人民南路9号公司会议室举行。本次 会议应出席会议的董事9人，实际出席会议的董事9人，全体监事及高级管理人员 列席了会议。会议由公司董事长邹洵先生主持，会议召开程序符合《公司法》和 《公司章程》的有关规定。 二、董事会会议审议情况 1.审议通过了公司《2024年第三季度报告》（同意票9票，反对票0票，弃权 票0票）。 本事项已经公司第八届董事会审计委员会审议并取得了明确同意的意见。 【详细内容见2024年10月30日《中国证券报》《证券时报》《证券日报》及 巨潮资讯网（http://www.cninfo.com.cn）发布的公司《2024年第三季度报告》】 2.审议通过了 ...

证券代码：002275 证券简称：桂林三金 公告编号：2024-029 第 1 页 共 2 页 东回报规划》关于利润分配政策规定的相关要求，同时兼顾了股东的即期利益和 长远利益，与公司经营业绩及未来发展相匹配，不存在损害中小股东利益的情形。 桂林三金药业股份有限公司 关于2024年前三季度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 桂林三金药业股份有限公司（以下简称"公司"）于2024年10月29日召开第 八届董事会第十一次会议、第八届监事会第八次会议，审议通过了公司《2024 年前三季度利润分配预案》，该议案需提交公司2024年第一次临时股东大会审议 通过后方可实施。具体内容如下： 一、2024年前三季度利润分配预案情况 根据公司2024年第三季度报告（未经审计），公司2024年1-9月实现归属于 上市公司股东的净利润为383,875,851.70元，截至2024年9月30日，公司合并资 产负债表未分配利润为1,465,026,651.04元，母公司资产负债表未分配利润为 2,221,750,664.83元。 2024年前三季度利润分 ...